Trials / NCT06912633
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Underway, not enrolling Phase 2 Cell therapy
- Sponsor
- jCyte, Inc
- Treatment
- human retinal progenitor cells; Mock injection
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Started
- 2025-06-20
- Main results expected
- 2026-12
- Results posted
- Not yet
- Record last updated
- 2026-07-30
What the study is testing
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.
Where it runs
United States (12)
- Associated Retina Consultants, Phoenix, Arizona
- California Retina Consultants, Bakersfield, California
- Retina-Vitreous Associates Medical Group, Beverly Hills, California
- Gavin Herbert Eye Institute, UC Irvine, Irvine, California
- Retina Consultants Medical Group, Sacramento, California
- Vitreo Retinal Associates, Gainesville, Florida
- Illinois Retina Associates, Oak Park, Illinois
- NJRetina, Teaneck, New Jersey
- Long Island Vitreoretinal Consultants, Westbury, New York
- Retina Consultants of Texas: Bellaire Retina Center, Bellaire, Texas
- Retina Consultants of Texas: San Antonio, San Antonio, Texas
- The Retina Group of Washington, Fairfax, Virginia